Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP

Science

Volumn 265, Issue 5180, 1994, Pages 1878-1882

  Weisskopf, Marc G ^a   Castillo, Pablo E ^a   Zalutsky, Robert A ^a   Nicoll, Roger A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; FORSKOLIN; PRESYNAPTIC RECEPTOR;

ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; GLUTAMIC ACID RELEASE; HIPPOCAMPUS; LONG TERM POTENTIATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0028051845     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.7916482     Document Type: Article

References (66)

1. T. V. P. Bliss and G. L. Collingridge, Nature 361, 31 (1993); R. C. Malenka and R. A. Nicoll, Trends Neurosci. 16, 521 (1993).
2. T. V. P. Bliss and G. L. Collingridge, Nature 361, 31 (1993); R. C. Malenka and R. A. Nicoll, Trends Neurosci. 16, 521 (1993).
3. E. W. Harris and C. W. Cotman, Neurosci. Lett. 70, 132 (1986).
4. R. A. Zalutsky and R. A. Nicoll, Science 248, 1619 (1990).
5. H. Katsuki, S. Kaneko, A. Tajima, M. Satoh, Neurosci. Res. 12, 393 (1991); R. B. Langdon, J. W. Johnson, G. Barrionuevo, Soc. Neurosci, Abstr. 19, 433 (1993).
6. H. Katsuki, S. Kaneko, A. Tajima, M. Satoh, Neurosci. Res. 12, 393 (1991); R. B. Langdon, J. W. Johnson, G. Barrionuevo, Soc. Neurosci, Abstr. 19, 433 (1993).
7. P. E. Castillo, M. G. Weisskopf, R. A. Nicoll, Neuron 12, 261 (1994).
8. D. Jaffe and D. Johnston, J. Neurophysiol. 64, 948 (1990); S. Williams and D. Johnston, Neuron 3, 583 (1989).
9. D. Jaffe and D. Johnston, J. Neurophysiol. 64, 948 (1990); S. Williams and D. Johnston, Neuron 3, 583 (1989).
10. U. Staubli, J. Larson, G. Lynch, Synapse 5, 333 (1990).
11. These results have appeared in abstract form [M. G. Weisskopf, R. A. Zalutsky, R. A. Nicoll, Soc. Neurosci. Abstr. 19, 1708 (1993)].
12. 2O with 1% ascorbic acid.
13. 2O with 1% ascorbic acid.
14. K. B. Seamon and J. W. Daly, Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20, 1 (1986).
15. W. F. Hopkins and D. Johnston, J. Neurophysiol. 59, 667 (1988). However, our results differ in two important respects from these earlier results: The effect seen in our study is long lasting and it occludes with LTP (see Figs. 2 and 4).
16. T. Hoshi, S. S. Garber, R. W. Aldrich, Science 240, 1652 (1988); A. Laurenza, E. M. Sutkowski, K. B. Seamon, Trends Pharmacol. Sci. 10, 442 (1989).
17. T. Hoshi, S. S. Garber, R. W. Aldrich, Science 240, 1652 (1988); A. Laurenza, E. M. Sutkowski, K. B. Seamon, Trends Pharmacol. Sci. 10, 442 (1989).
18. W. R. G. Dostmann et al., J. Biol. Chem. 265, 10484 (1990).
19. P. J. M. Van Haastert et al., ibid. 259, 10020 (1984).
20. A similar depression was seen with the analogs 8-bromo-cAMP (n = 7) and dibutyryl cAMP (n = 3), but little enhancement. This inhibition, as well as that seen with Sp-cAMPS in the presence of forskolin, may result from an action on adenosine A1 presynaptic receptors, but attempts to unmask an enhancement with A1 antagonists were not possible because of the epileptiform activity induced by the antagonists in the CA3 region.
21. D. V. Madison and R. A. Nicoll, J. Physiol. (London) 372, 245 (1986).
22. J. Egebjerg, B. Settler, I. Hermans-Borgmeyer, S. Heinemann, Nature 351, 745 (1991).
23. L.-Y. Wang, F. A. Taverna, X.-P. Huang, J. F. Mac-Donald, D. R. Hampson, Science 259, 1173 (1993); L. A. Raymond, C. D. Blackstone, R. L. Huganir, Nature 361, 637 (1993).
24. L.-Y. Wang, F. A. Taverna, X.-P. Huang, J. F. Mac-Donald, D. R. Hampson, Science 259, 1173 (1993); L. A. Raymond, C. D. Blackstone, R. L. Huganir, Nature 361, 637 (1993).
25. D. Dixon and H. L. Atwood, J. Neurosci. 9, 4246 (1989).
26. K. P. Scholz and J. H. Byme, Science 240, 1664 (1988); S. Schacher, V. F. Castellucci, E. R. Kandel, ibid., p. 1667.
27. K. P. Scholz and J. H. Byme, Science 240, 1664 (1988); S. Schacher, V. F. Castellucci, E. R. Kandel, ibid., p. 1667.
28. K. Kuba and E. Kumamoto, J. Physiol. (London) 374, 515 (1986).
29. L. E. Chavez-Noriega and C. F. Stevens, J. Neurosci. 14, 310 (1994).
30. Glutamate was used in these experiments rather than a non-NMDA agonist because it is rapidly removed by uptake, thus its action is localized. In addition, responses similar in size to the synaptic response were used to restrict, as well as possible, the activation of glutamate receptors in the stratum lucidum, close to the recorded synaptic response.
31. B. Katz and R. Miledi, J. Physiol. (London) 195, 481 (1968); A. Mallart and A. R. Martin, ibid. 196, 593 (1968); R. S. Zucker, Annu. Rev. Neurosci. 12, 13 (1989); T. Manabe, D. J. A. Wyllie, D. J. Perkel, R. A. Nicoll, J. Neurophysiol. 70, 1451 (1993).
32. B. Katz and R. Miledi, J. Physiol. (London) 195, 481 (1968); A. Mallart and A. R. Martin, ibid. 196, 593 (1968); R. S. Zucker, Annu. Rev. Neurosci. 12, 13 (1989); T. Manabe, D. J. A. Wyllie, D. J. Perkel, R. A. Nicoll, J. Neurophysiol. 70, 1451 (1993).
33. B. Katz and R. Miledi, J. Physiol. (London) 195, 481 (1968); A. Mallart and A. R. Martin, ibid. 196, 593 (1968); R. S. Zucker, Annu. Rev. Neurosci. 12, 13 (1989); T. Manabe, D. J. A. Wyllie, D. J. Perkel, R. A. Nicoll, J. Neurophysiol. 70, 1451 (1993).
34. B. Katz and R. Miledi, J. Physiol. (London) 195, 481 (1968); A. Mallart and A. R. Martin, ibid. 196, 593 (1968); R. S. Zucker, Annu. Rev. Neurosci. 12, 13 (1989); T. Manabe, D. J. A. Wyllie, D. J. Perkel, R. A. Nicoll, J. Neurophysiol. 70, 1451 (1993).
35. This was not due to an enhanced excitability of the dentate granule cells for two reasons: Forskolin had no effect on the fiber volley recorded in the presence of CNQX, whereas increasing the stimulus strength to produce synaptic responses similar to those seen after forskolin application did increase the fiber volley (n = 3); and norepinephrine, which causes a cAMP-dependent increase in granule cell excitability [H. L. Haas and G. M. Rose, Neurosci. Lett. 78, 171 (1987)], did not enhance mossy fiber synaptic responses (n = 5).
36. The agonists, which were all tested in at least three slices, included isoproterenol (100 μM) to activate β-adrenergic receptors, 5-HT (100 μM) to activate 5-HT4 receptors, DPMA (100 nM) to activate adenosine A2 receptors [A. J. Bridges et al., J. Med. Chem. 31, 1282 (1988)], dimaprit (100 μM) to activate histamine H2 receptors [M. E. Parsons, D. A. A. Owen, C. R. Ganellin, G. J. Durant, Agents Actions 7, 31 (1977)], and PACAP-27(1 μM) to activate VIP and Type 1 PACAP receptors. Type 1 PACAP receptor mRNA is expressed at high concentrations in dentate granule cells [H. Hashimoto et al., Neuron 11, 333 (1993)].
37. The agonists, which were all tested in at least three slices, included isoproterenol (100 μM) to activate β-adrenergic receptors, 5-HT (100 μM) to activate 5-HT4 receptors, DPMA (100 nM) to activate adenosine A2 receptors [A. J. Bridges et al., J. Med. Chem. 31, 1282 (1988)], dimaprit (100 μM) to activate histamine H2 receptors [M. E. Parsons, D. A. A. Owen, C. R. Ganellin, G. J. Durant, Agents Actions 7, 31 (1977)], and PACAP-27(1 μM) to activate VIP and Type 1 PACAP receptors. Type 1 PACAP receptor mRNA is expressed at high concentrations in dentate granule cells [H. Hashimoto et al., Neuron 11, 333 (1993)].
38. The agonists, which were all tested in at least three slices, included isoproterenol (100 μM) to activate β-adrenergic receptors, 5-HT (100 μM) to activate 5-HT4 receptors, DPMA (100 nM) to activate adenosine A2 receptors [A. J. Bridges et al., J. Med. Chem. 31, 1282 (1988)], dimaprit (100 μM) to activate histamine H2 receptors [M. E. Parsons, D. A. A. Owen, C. R. Ganellin, G. J. Durant, Agents Actions 7, 31 (1977)], and PACAP-27(1 μM) to activate VIP and Type 1 PACAP receptors. Type 1 PACAP receptor mRNA is expressed at high concentrations in dentate granule cells [H. Hashimoto et al., Neuron 11, 333 (1993)].
39. In a first series of experiments, we only compared the effect of forskolin on a naïve pathway and on a pathway that had received the repeated tetanic stimuli that were used to maximize LTP. Thus, we examined the differential effect of forskolin in 12 slices, whereas the effect of forskolin on single-tetanus LTP was compared in 5 slices. For these five slices, the effect of forskolin at 15 to 20 min was significantly different between the two pathways (P < 0.02).
40. T. Chijiwa et al., J. Biol. Chem. 265, 5267 (1990); M. Wieprecht, T. Wieder, C. C. Geilen, Biochem. J. 297, 241 (1994).
41. T. Chijiwa et al., J. Biol. Chem. 265, 5267 (1990); M. Wieprecht, T. Wieder, C. C. Geilen, Biochem. J. 297, 241 (1994).
42. H. Käse et al., Biochem. Biophys. Res. Commun. 142, 436 (1987); L. Cabell and G. Audesirk, Int. J. Dev. Neurosci. 11, 357 (1993).
43. H. Käse et al., Biochem. Biophys. Res. Commun. 142, 436 (1987); L. Cabell and G. Audesirk, Int. J. Dev. Neurosci. 11, 357 (1993).
44. The short-term potentiation remaining in the presence of the antagonists could indicate that this early phase is mechanistically different from the late phase, or, more simply, it represents an incomplete blockade that is due to inadequate concentrations of antagonist in the terminal.
45. U. Frey, Y.-Y. Huang, E. R. Kandel, Science 260, 1661 (1993); H. Matthies and K. G. Reymann, Neuroreport 4, 712 (1993); Y.-Y. Huang and E. R. Kandel, Learn. Mem. 1, 74 (1994).
46. U. Frey, Y.-Y. Huang, E. R. Kandel, Science 260, 1661 (1993); H. Matthies and K. G. Reymann, Neuroreport 4, 712 (1993); Y.-Y. Huang and E. R. Kandel, Learn. Mem. 1, 74 (1994).
47. U. Frey, Y.-Y. Huang, E. R. Kandel, Science 260, 1661 (1993); H. Matthies and K. G. Reymann, Neuroreport 4, 712 (1993); Y.-Y. Huang and E. R. Kandel, Learn. Mem. 1, 74 (1994).
48. S. Minota, E. Kumamoto, O. Kitakoga, K. Kuba, J. Physiol. (London) 435, 421 (1991).
49. C. A. Briggs, T. H. Brown, D. A. McAfee, ibid. 359 503 (1985); C. A. Briggs and D. A. McAfee, ibid. 404, 129 (1988).
50. C. A. Briggs, T. H. Brown, D. A. McAfee, ibid. 359 503 (1985); C. A. Briggs and D. A. McAfee, ibid. 404, 129 (1988).
51. J. M. Wojtowicz and H. L. Atwood, J. Neurosci. 8, 4667 (1988).
52. D. A. Baxter, G. D. Bittner, T. H. Brown, Proc. Natl. Acad. Sci. U.S.A. 82, 5978 (1985).
53. I. Ito and H. Sugiyama, Neuroreport 2, 333 (1991).
54. R. D. Hawkins, E. R. Kandel, S. A. Siegelbaum, Annu. Rev. Neurosci. 16, 625 (1993); J. H. Byme, R. Zwartjes, R. Homayouni, S. D. Critz, A. Eskin, in Advances in Second Messenger and Phosphoprotein Research, S. Shenolikar and A. C. Nairn, Eds. (Raven, New York, 1993), vol. 27, pp. 47-108.
55. R. D. Hawkins, E. R. Kandel, S. A. Siegelbaum, Annu. Rev. Neurosci. 16, 625 (1993); J. H. Byme, R. Zwartjes, R. Homayouni, S. D. Critz, A. Eskin, in Advances in Second Messenger and Phosphoprotein Research, S. Shenolikar and A. C. Nairn, Eds. (Raven, New York, 1993), vol. 27, pp. 47-108.
56. Y. Dudai, Annu. Rev. Neurosci. 11, 537 (1988).
57. J. M. Sarvey, in Long-Term Potentiation: From Biophysics to Behavior, P. W. Landsfield and S. A. Deadwyler, Eds. (Liss, NY, 1988), pp. 329-353.
58. P. F. Woriey, J. M. Baraban, E. B. DeSouza, S. H. Snyder, Proc. Natl. Acad. Sci. U.S.A. 83, 4053 (1986).
59. 2+-calmodulin-sensitive and is expressed in hippocampal neurons, has recently been described [J. J. Cali et al., J. Biol. Chem. 269, 12190 (1994)].
60. 2+-calmodulin-sensitive and is expressed in hippocampal neurons, has recently been described [J. J. Cali et al., J. Biol. Chem. 269, 12190 (1994)].
61. Z. Xia, C. D. Refsdal, K. M. Merchant, D. M. Dorsa, D. R. Storm, Neuron 6, 431 (1991); C. E. Glatt and S. H. Snyder, Nature 361, 536 (1993).
62. Z. Xia, C. D. Refsdal, K. M. Merchant, D. M. Dorsa, D. R. Storm, Neuron 6, 431 (1991); C. E. Glatt and S. H. Snyder, Nature 361, 536 (1993).
63. W. G. Regehr and D. W. Tank, Neuron 7, 451 (1991); W. G. Regehr, K. R. Delaney, D. W. Tank, J. Neurosci. 14, 523 (1994).
64. W. G. Regehr and D. W. Tank, Neuron 7, 451 (1991); W. G. Regehr, K. R. Delaney, D. W. Tank, J. Neurosci. 14, 523 (1994).
65. Z. Wu, S. T. Wong, D. R. Storm, J. Biol. Chem, 268, 23766 (1993).
66. We thank H. Bourne, D. Copenhagen, D. Dixon, and D. Wyllie for their comments on the manuscript and R. Kramer for suggesting the use of Rp-8-CPT-cAMPS. Supported by the National Institutes of Mental Health. M.G.W. was supported by a University of California, San Francisco Chancellor's Fellowship. P.E.C. was supported by the Fogarty International Center of NIH. R.A.N. is a member of the Keck Center for Integrative Neuroscience and the Silvio Conte Center for Neuroscience Research.